David Rimm MD, PhD

home / authors / david-rimm-md-phd

Articles

David Rimm, MD, PhD

Dr Rimm on Unmet Needs in Distinguishing Between HER2-Low and HER2-Ultralow Breast Cancer

David Rimm MD, PhD
June 26th 2024

David Rimm, MD, PhD, discusses challenges in distinguishing between HER2-low and HER2-ultralow breast cancer using current diagnostic kits.

Read More

David Rimm, MD, PhD

Dr. Rimm on the Use of Multiplex Spatial Proteomic Profiling in Breast Cancer

David Rimm MD, PhD
March 14th 2023

David Rimm, MD, PhD, discusses both the use and advantages of utilizing multiplex spatial proteomic profiling in breast cancer.

Read More

Dr. David Rimm on Immunofluorescence for HER2 Identification

Dr. David Rimm on Immunofluorescence for HER2 Identification

David Rimm MD, PhD
January 26th 2015

David Rimm MD, PhD, professor of pathology and medicine, director of pathology tissue services, Yale University School of Medicine, explains the benefits of quantitativecfor the measurement of HER2 proteins.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Mark Agulnik, MD
Published: July 16th 2024 | Updated: July 23rd 2024
Dr Agulnik on the Evolving Management of Heterogenous Disease in GIST
Ciara Kelly, MBBCh, BAO
Published: July 16th 2024 | Updated: July 23rd 2024
Dr Kelly on the Role of Ripretinib in the GIST Treatment Paradigm
Neil D. Gross, MD, FACS
Published: July 10th 2024 | Updated: July 23rd 2024
Neoadjuvant Cemiplimab Underscores Push to Bolster Treatment of CSCC
5 KOLs are featured in this panel.
Published: July 17th 2024 | Updated: July 23rd 2024
Exploring Data Outcomes From the SUNLIGHT Trial